Ever since Anavex Life Sciences Corp (OTCMKTS:AVXL) unveiled the finding of a new report, its stock price has been moving up remarkably. Friday was no less an exception when the stock price of the company moved back in the green to settle at $0.330, higher by close to 14%. The average share trade volume of the company recorded on the day stood at 1.89 million shares.

Sigma-1 receptor activation

The most relevant press release by the company was published during late April when it noted the review on the company’s Sigma-1 receptor agonists that appeared in Neuroscience Letters, a Scientific journal.

The review highlighted the real-time study that showed the effectiveness of sigma-1 receptor in overcoming the devastating effects of microglial inflammation. On activation, sigma-1 receptor helps in reducing the negative response, which are caused by Chronic microglia that leads to neurodegenerative diseases, including Alzheimer’s disease and brain injury.

Establishes the fact For ANAVEX

Anavex Life Sciences Corp (OTCMKTS:AVXL) commented that the findings published in the journal were inspiring and helped establish the fact that the sigma-1 receptor has power to control the neurodegenerative diseases. The review published in the journal further signifies the role of Anavex Life Sciences Corp (OTCMKTS:AVXL)’s sigma-1 receptor agonists, including ANAVEX 2-73, which is presently put under a Phase 2a clinical study to treat Alzheimer’s disease. The company drew important indications from the review that sigma-1 receptor activity could be accelerated through agonists, which in turn, will help nullify the impact of neuro inflammation and other associated symptoms.

The company found the report findings convincing to reach a conclusion that its work on activating sigma-1 receptor bears a lot of importance. The company’s CEO Christopher U. Missling too expressed content over the findings and was confident that ANAVEX 2-73 will successfully minimize the impact of microglia inflammation.

Previous articleMind Solutions Inc (OTCMKTS:VOIS) Betting High On Its BCI, “NeuroSync.”
Next articleIs It Another Pump For Pharmacyte Biotech Inc (OTCMKTS:PMCB)?
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.